194 related articles for article (PubMed ID: 19065124)
1. Impact of optimal medical therapy and percutaneous coronary intervention on patients with stable angina.
Latib A; Chieffo A; Colombo A
Nat Clin Pract Cardiovasc Med; 2009 Feb; 6(2):92-3. PubMed ID: 19065124
[TBL] [Abstract][Full Text] [Related]
2. Interpreting the results of the COURAGE trial: a non-interventionalist perspective.
Boden WE
Rev Cardiovasc Med; 2009; 10 Suppl 2():S34-44. PubMed ID: 19898280
[TBL] [Abstract][Full Text] [Related]
3. Impact of treatment strategies on outcomes in patients with stable coronary artery disease and type 2 diabetes mellitus according to presenting angina severity: A pooled analysis of three federally-funded randomized trials.
Mancini GBJ; Boden WE; Brooks MM; Vlachos H; Chaitman BR; Frye R; Bittner V; Hartigan PM; Dagenais GR
Atherosclerosis; 2018 Oct; 277():186-194. PubMed ID: 29861270
[TBL] [Abstract][Full Text] [Related]
4. One year perspective on COURAGE.
Tommaso CL
Catheter Cardiovasc Interv; 2008 Sep; 72(3):426-429. PubMed ID: 18727125
[TBL] [Abstract][Full Text] [Related]
5. Clinical implications of the BARI 2D and COURAGE trials: the evolving role of percutaneous coronary intervention.
Holper EM; Addo T
Coron Artery Dis; 2010 Nov; 21(7):397-401. PubMed ID: 20634692
[TBL] [Abstract][Full Text] [Related]
6. Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention.
Borden WB; Redberg RF; Mushlin AI; Dai D; Kaltenbach LA; Spertus JA
JAMA; 2011 May; 305(18):1882-9. PubMed ID: 21558519
[TBL] [Abstract][Full Text] [Related]
7. Re: One year perspective on COURAGE.
Sedlis SP; Boden WE; Weintraub WS; Maron DS; O'Rourke RA; Berman DS; Mancini GB;
Catheter Cardiovasc Interv; 2009 Feb; 73(3):428. PubMed ID: 19133682
[No Abstract] [Full Text] [Related]
8. Health status and quality of life in patients with stable coronary artery disease and chronic kidney disease treated with optimal medical therapy or percutaneous coronary intervention (post hoc findings from the COURAGE trial).
Sedlis SP; Jurkovitz CT; Hartigan PM; Kolm P; Goldfarb DS; Lorin JD; Dada M; Maron DJ; Spertus JA; Mancini GB; Teo KK; Boden WE; Weintraub WS;
Am J Cardiol; 2013 Dec; 112(11):1703-8. PubMed ID: 24011740
[TBL] [Abstract][Full Text] [Related]
9. Predicting the Benefits of Percutaneous Coronary Intervention on 1-Year Angina and Quality of Life in Stable Ischemic Heart Disease: Risk Models From the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation).
Zhang Z; Jones P; Weintraub WS; Mancini GBJ; Sedlis S; Maron DJ; Teo K; Hartigan P; Kostuk W; Berman D; Boden WE; Spertus JA
Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e003971. PubMed ID: 29752388
[TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of percutaneous coronary intervention as a function of angina severity in patients with stable angina.
Zhang Z; Kolm P; Boden WE; Hartigan PM; Maron DJ; Spertus JA; O'Rourke RA; Shaw LJ; Sedlis SP; Mancini GB; Berman DS; Dada M; Teo KK; Weintraub WS
Circ Cardiovasc Qual Outcomes; 2011 Mar; 4(2):172-82. PubMed ID: 21304091
[TBL] [Abstract][Full Text] [Related]
11. Ischemia is the critical determinant of revascularization benefit: an interventionalist's perspective of the COURAGE trial.
Kereiakes DJ
Rev Cardiovasc Med; 2009; 10 Suppl 2():S45-52. PubMed ID: 19898281
[TBL] [Abstract][Full Text] [Related]
12. Percutaneous coronary intervention for stable patients: is there any benefit beyond symptom relief?
Stankovic G
Arq Bras Cardiol; 2009 Aug; 93(2):196-9. PubMed ID: 19838499
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic strategies in patients with chronic stable coronary artery disease.
Zellweger MJ; Pfisterer ME
Cardiovasc Ther; 2011 Dec; 29(6):e23-30. PubMed ID: 20491783
[TBL] [Abstract][Full Text] [Related]
14. Should percutaneous revascularization for stable coronary artery disease be performed sooner or later?
Prasad A; Gersh BJ
JACC Cardiovasc Interv; 2008 Oct; 1(5):480-2. PubMed ID: 19463348
[No Abstract] [Full Text] [Related]
15. Quantitative results of baseline angiography and percutaneous coronary intervention in the COURAGE trial.
Mancini GB; Bates ER; Maron DJ; Hartigan P; Dada M; Gosselin G; Kostuk W; Sedlis SP; Shaw LJ; Berman DS; Berger PB; Spertus J; Mavromatis K; Knudtson M; Chaitman BR; O'Rourke RA; Weintraub WS; Teo K; Boden WE;
Circ Cardiovasc Qual Outcomes; 2009 Jul; 2(4):320-7. PubMed ID: 20031857
[TBL] [Abstract][Full Text] [Related]
16. The immediate impact of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial on the management of stable angina.
Atwater BD; Oujiri J; Wolff MR
Clin Cardiol; 2009 Aug; 32(8):E1-3. PubMed ID: 19536842
[TBL] [Abstract][Full Text] [Related]
17. Timing of staged percutaneous coronary intervention in multivessel coronary artery disease.
Dangas GD; George JC; Weintraub W; Popma JJ
JACC Cardiovasc Interv; 2010 Oct; 3(10):1096-9. PubMed ID: 20965476
[No Abstract] [Full Text] [Related]
18. Percutaneous coronary intervention plus medical therapy reduces the incidence of acute coronary syndrome more effectively than initial medical therapy only among patients with low-risk coronary artery disease a randomized, comparative, multicenter study.
Nishigaki K; Yamazaki T; Kitabatake A; Yamaguchi T; Kanmatsuse K; Kodama I; Takekoshi N; Tomoike H; Hori M; Matsuzaki M; Takeshita A; Shimbo T; Fujiwara H;
JACC Cardiovasc Interv; 2008 Oct; 1(5):469-79. PubMed ID: 19463347
[TBL] [Abstract][Full Text] [Related]
19. Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trial.
Teo KK; Sedlis SP; Boden WE; O'Rourke RA; Maron DJ; Hartigan PM; Dada M; Gupta V; Spertus JA; Kostuk WJ; Berman DS; Shaw LJ; Chaitman BR; Mancini GB; Weintraub WS;
J Am Coll Cardiol; 2009 Sep; 54(14):1303-8. PubMed ID: 19778673
[TBL] [Abstract][Full Text] [Related]
20. Frequency, predictors, and consequences of crossing over to revascularization within 12 months of randomization to optimal medical therapy in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial.
Spertus JA; Maron DJ; Cohen DJ; Kolm P; Hartigan P; Weintraub WS; Berman DS; Teo KK; Shaw LJ; Sedlis SP; Knudtson M; Aslan M; Dada M; Boden WE; Mancini GB;
Circ Cardiovasc Qual Outcomes; 2013 Jul; 6(4):409-18. PubMed ID: 23838107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
